Cell therapy for hard-to-treat autoimmune hemolytic anemia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia that hasn't improved after other treatments. The goal is to see if this therapy can help control the disease and be safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with autoimmune hemolytic anemia (AIHA) or Evans syndrome (which causes your body to attack its own red blood cells).
- You have already tried at least three standard treatments (like steroids or rituximab), and your anemia is still not under control (your hemoglobin is below 100 g/L).
- Your major organs (liver, kidneys, heart, lungs) and blood counts are within certain safe limits for this study.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use contraception for 12 months after treatment.
- You have not had certain recent treatments (like rituximab in the last 12 weeks, plasma exchange in the last 4 weeks, or spleen removal in the last 12 weeks), and you have not had CAR-T therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can help control the anemia and reduce the need for ongoing treatments.
This trial tests a new cell treatment called YTS109 for people with autoimmune hemolytic anemia (AIHA) that has not improved after several standard treatments. The goal is to see if this treatment can help control the disease.
This trial tests a new type of cell therapy (called CAR-T) for people with autoimmune hemolytic anemia or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can control the condition and reduce the need for ongoing immune-suppressing drugs.
This trial tests a new medicine for people with autoimmune hemolytic anemia (AIHA) that has not improved with standard treatments. The goal is to see if the drug can help control the disease and improve red blood cell counts.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This study tests a new drug called enatumab that may help people with a type of autoimmune anemia where the body attacks its own red blood cells. If you have not responded to previous treatments or your condition has returned, this trial might offer a new option to improve your hemoglobin levels.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.